The document contains information about vaccination rates in adolescents from 2006-2008. It shows that rates of HPV vaccination and meningitis vaccination increased over this period but rates of whooping cough and tetanus vaccination were still below the Healthy People 2010 goal of 80% in 2008. Free and low-cost vaccines are available through programs like the Vaccines for Children program.

1. 2
Portfolio | Jim Winslow
> Infographics: Charts
Percent Immunized
0 10 20 30 40 50 60 70 80
HPV 1+
MCV
Tdap
TD/Tdap
2006
2007
2008
Source: National Foundation for Iinfectious Diseases
Data derived from Centers for Disease Control and Prevention (CDC). Estimated
Vaccine Coverage With Selected Vaccines Among Adolescents Aged 13-17 Years, by
State and Selected Local Areas – National Immunization Survey-Teen, United States,
2006, 2007, 2008.Atlanta, Georgia: U.S. Department of Health and Human
Services, CDC, 2006, 2007, 2008.
60.1
10.8
30.4
40.8
11.7
32.4
41.8
25.1
17.9
72.3
72.2
19.3
Figure 1
Vaccination Rates in Adolescents
13-17 Years of Age, U.S.—2006-08
2008 Rates for
1 dose and 3 doses
1 Dose
3≥ Doses
Group NHANES
1976-1980
2003-2004
Adults
aged 20-74 years
Adolescents
aged 12-19 years
Children
aged 6-11 years
Children
2-5 years
15.0%
5.0%
6.5%
17.4%
18.8%
13.9%
5.0%
32.9%
Prevalence of Obesity* 1976-1980 to 2003-2004
Composition of HFCS
Composition
of Sucrose
HFCS
in Beverages
HFCS
in Baked Goods
Fructose
50%
Glucose
50%
Fructose
55%
Polysaccharides
(glucose polymers)
1-3%
Polysaccharides
(glucose polymers)
4-6%
Glucose
42-44%
Fructose
42%
Glucose
52-54%
* Using 95th percentile of Body Mass index for children and adolescents 2-19 years of age.
0
10
20
30
40
50
20102009200820072006200520042003
Newspaper Ad Revenues Versus Google Ad Revenues
Billions
Source: Newspaper Association of America.
http://www.naa.org/Trends-and-Numbers/Advertising-Expenditures/Annual-All-Categories.aspx
Google ad reveune from Yahoo Finance
$46.2b
$49.3b
53.0% Drop in Expenditures
287.7% Rise in Revenues
$25.9b
$10.5b
$36.5b
Total Newspaper Advertising Expenditures, Print & Online
Google Ad Revenue
1.4b
> Charts and graphics created in Illustrator

2. 3
Portfolio | Jim Winslow
> Infographics: Charts
30.4% 32.4%
41.8%40.8%
80%
2007
Healthy People
2010 Goal
Whooping Cough Meningitis
Whooping Cough & Meningitis Vaccination Rates Among Teens Are
Increasing But Still Fall Short of Healthy People 2010 Goals of 80%
Free and low-cost vaccine available through national Vacciones for Children program;
visit your local health department to learn more
2007
20082008
Vaccination Rates forTeens 13-17Years Old
Source:Centers for Disease Control and Prevention
> Charts and graphics created in Illustrator
A GfK Roper telephone survey of 1005 adults aged 18 and older was completed, with 663 among the target subgroup of adults aged 18-64.
The margin of error for this study is +/- 3 percentage points for total sample and is higher for subgroups.
This survey was sponsored by Sanofi Pasteur, the vaccines division of Sanofi. For more information visit www.fluzone.com.
Spreading the Flu to Family and Friends Scares
More Adults than Common Halloween Frights
67%39%
The Dark Movies Black Widow
Spiders
Spreading the Flu
to Loved Ones
9%
24%
Yet, Few Take Action!
Even though everyone 6 months of age and older should be vaccinated1
3 in 5 adults remain unvaccinated, leaving many vulnerable to influenza
Talk to your health care provider
or pharmacist about flu vaccine options.
Reference:
1. Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the Advisory
Committee on Immunization Practices (ACIP), 2011. MMWR. 2011;60(33):1128-1132.
COM10698
Meningitis
80%
0%
20%
40%
60%
HealthyPeople2010Goal
Whooping Cough
Whooping Cough & MeningitisVaccination Rates AmongTeens Are
Increasing But Still Fall Short of HealthyPeople2010Goals of 80%
Free and low-cost vaccine available through nationalVaccines for Children program;
visit your local health department to learn more
Vaccination Rates for Teens 13-17 Years Old
Source:Centers for Disease Control and Prevention
32.4%
41.8%
20082007
30.4%
40.8%
2007 2008
Males immune to diphtheria
Females immune to diptheria
6-11 12-19 20-19 30-39 40-49 50-59 60-69 Over 70
Immunity to Diptheria Declines With Age
Immunity%
100
80
60
40
20
0
Age
0
10
20
30
40
50
60
70
80
90
Farming
or gardening
31%
At home
or indoors
45%
Outdoor
activities
23%
Auto Accident 1%
Source: CDC
Sources of Tetanus Injuries
...protection is lowest in older Americans
While most Americans are protected
against diphtheria and tetanus...
Immunity%
Protection Against Diphtheria and Tetanus
Full protection
against diphtheria
Full protection
against diphtheria
and tetanus
Full protection
against diphtheria
and tetanus
Full protection
against tetanus
6 years of age and older 6-11 years of age Over 70 years of age
60.5%
91%
72.3%
31%
2 in 3 say their biggest fear regarding influenza is spreading it to friends
and family
Increases Vaccination Rates!
Adults 18 to 64
Fluzone Intradermal vaccine is a safe and effective way to help prevent influenza. Redness, firmness, swelling, and
itching at the injection site occur more frequently with Fluzone Intradermal vaccine than Fluzone vaccine. Other
common side effects include pain, headache, fatigue, and muscle aches.
A telephone survey of 1005 adults aged 18 and older was completed, with
663 among the target subgroup of adults aged 18-64. The margin of error
for this study is +/- 3 percentage points for total sample and is higher for
subgroups.
To find out where to get Fluzone Intradermal, visit Fluzone.com,
or talk to your health care provider or pharmacist for more information
Smaller
Needle90%
Alternative technologies,
such as Fluzone Intradermal
vaccine, which has a 90%
smaller needle, provides new
strategy
Are You Spreading The Flu?
Yet, 3 in 5 adults remain unprotected against the flu
About 5 to 20 percent of the population get influenza annually1
Reference:
1. Centers for Disease Control and Prevention (CDC). Seasonal influenza (flu) – q&a: seasonal influenza (flu): the
disease. http://www.cdc.gov/flu/about/qa/disease.htm. Accessed June 25, 2012.

3. 4
Portfolio | Jim Winslow
> Infographics: Timelines
Influenza Vaccine Timeline Timing of egg-based and cell culture production
4Determines amount/
yield of virus strains
4Purity and potency tested
4The 3 strains are blended into
1 vaccine by the manufacturer
4FDA licenses the vaccine
4Vaccine is filled into
vials and syringes
4Vaccine is packaged
for distribution
4Kept in cold storage
to ensure potency
4Shipping of
influenza
vaccine begins
Production begins
Virus selection
4FDA advisory panel selects 3 strains
4CDC provides new strains of the
seed virus to the FDA
4FDA distributes the 3 seed viruses to
manufacturers
January February March April May June July August September
4Seed virus resorted with reference virus*
4Seed virus is injected into fertilized chicken eggs
4Virus multiplies in incubated eggs
4Allantoic fluid (egg white) is removed, virus is
harvested
4Chemical treatment applied – ensures virus is
inactivated
4Multiple purifications throughout process
*Resorting improves virus yield in egg-based production but has
not been shown to affect yield in cell culture production
FDA tests to confirm production
Filling/Packaging
Egg-Based Production
Cell Culture Production FDA Testing
FDA Testing Packaging Shipping
ShippingPackaging4Cells grown in increasingly large vessels
4Flasks
4Bottles
4Small, medium, large bioreactors
4Mature cells inoculated with seed virus
4Virus multiples in cells
4Chemical treatment applied–ensures
virus is inactivated
4Multiple purifications throughout process
Theoretically, vaccine could be available up to 3 weeks
earlier using cell culture methods, however lower yields
compared with egg-based production may affect vaccine supply
> Timelines created in Illustrator
Pre-vaccine Era
Estimated 12,000–20,000 cases a year in U.S.: 3-6% fatal
1889 1920 1929 1933 1930-40 1950-70 1970s Early 1980s 1980s 1985 1987 1991 1995 1996-00 Present
[1929] Researchers create
first bacterial polysaccharide
conjugate vaccine*. Discovery
will serve as basis for
development of first conjugate
vaccine for Haemophilus
influenzae type b (Hib) 58 years
later.
* A conjugate vaccine is a vaccine that
has been “joined” to a protein in order
to improve the body’s response to
invading substances such as bacteria.
[1930-40] Pioneering research by Dr. Margaret
Pittman of the National Institutes of Health leads
to greater understanding of infections caused
by Hib and forms the basis for the first effective
treatments for invasive Hib disease. Dr. Pittman
observes that H. influenzae type b accounts for
nearly all strains that cause invasive disease.
[1970s] Research yields the first vaccine for
Hib, however vaccine effectiveness is limited
in children under 2 years of age.
[1980s] Researchers develop and test
conjugate vaccine for Hib.
Post-vaccine Era
Cases drop to an average of 68 a year in U.S.
Haemophilus influenzae
Hibdisease.com
[1985] First Hib vaccine licensed.
Vaccine is not effective in children
under 18 months of age.
■ 1889 Discovery of Hib bacteria
■ 1929 First vaccine prototype created
■ 1930-1940 First effective antibiotic treatments
■ 1980 Estimated 20,000 cases a year
■ 1987 First conjugate vaccine licensed
A Vaccine-preventable Disease
[1920] Scientists give name
Haemophilus (Latin for “blood
loving”) influenzae to the organism
to show its relationship to flu and
blood diseases.
[1933 ] Researchers establish that flu is a virus and that
H. influenzae is the result of a secondary infection, not the
cause of flu as earlier believed. Researchers also observe
that disease is most common in children under 5 years
of age. Later research will confirm the close relationship
between age and Hib disease. Occurrence of the disease
peaks at 6-7 months of age. Cases after 5 years of age
are uncommon.
[1950-70] Advances in antibiotics improve treatment,
but fail to make progress in eliminating Hib disease,
prompting the development and licensing of vaccines
over the next two decades. Hib continues to be
the most common cause of bacterial meningitis in
children under 5 years of age with approximately
12,000 cases a year. Bacterial meningitis is an
infection of the spinal fluid and tissues that surround
the brain and spinal cord.
Of those, 3-6% of cases
result in death. Up to 30%
of survivors suffer from
neurological disorders
including hearing loss,
seizures, and mental
retardation.
[Early 1980s] Annual cases in U.S.
estimated to be about 20,000, primarily
among children younger than 5 years
of age.
[1991] Routine immunization
with Hib conjugate vaccines
recommended by American
Academy of Pediatrics,
Committee on Infectious
Diseases and the U.S. Centers
for Disease Control and
Prevention (CDC).
[1889] Haemophilus influenzae
(H. influenzae) bacterium isolated
during the 1889 influenza (flu)
pandemic by Dr. Richard Pfeiffer.
Bacterium is believed at the time to
be a cause of flu.
[1995] CDC study finds that immunization
with conjugate Hib vaccines has
drastically changed the epidemiology of
bacterial meningitis, making it a disease
of adults rather than infants and young
children. Median age of cases rises from
15 months in 1986 to 25 years in 1995.
[Present] Hib cases in the U.S. have declined by more than 99% since the
introduction of vaccines. Three Hib vaccines are licensed for use in infants as young
as 6 weeks of age. All three have been shown to be highly effective.
Despite the amazing success of Hib vaccination in the U.S., Hib disease remains a
threat. Without high immunization rates, Hib could still strike at the same level (one in
200 children with a death rate of 5%) as before vaccines were available in the U.S.
Worldwide, Hib remains a major source of deaths and disabilities in children, with
an estimated three million cases of serious disease and as many as 700,000
deaths a year.
[1987] First conjugate vaccine licensed.
Technology used to create conjugate vaccines for
Hib serves as a model for vaccines developed in
the next decade.
Photo courtesy of CDC
[1996-2000] Hib cases fall
to an average of 68 cases
per year in U.S.
Learn More
> 4 color posters for print. Layout and design: InDesign,; graphics created in Illustrator and Photoshop
l The origin of the word
cancer is credited to the
Greek physician Hippocrates
(460-370 B.C.), considered
the “Father of Medicine.”
Hippocrates used the terms
carcinos and carcinoma to
describe non-ulcer forming
and ulcer-forming tumors
Joseph Claude Anthelm l
Recamier was the first
to recognise cancer
metastasis
l In 1953, James
Watson and Frances
Crick unleashed a
tidal wave of new
discoveries with
their model of
DNA’s structure.
Cancer researchers
contributed much of
this new information
as they continued
to search for “magic
bullets”
l The effects of cisplatin, a platinum
based compound, on cell division
is discovered and investigated by
Barnett Rosenberg at Michigan
State University. Platinum based
compounds are now an important
part of chemotherapy
l A major breakthrough - James
Holland, Emil Freireich and Emil
Frei hypothesised that cancer
chemotherapies could be used
in combination, each with a
different mechanism of action.
This quickly gained widespread
acceptance among cancer
clinicians
l Emil Frei and colleagues
first demonstrate that
chemotherapy given after
surgical removal of a tumour
(adjuvant therapy) improves
cure
l EUROPA DONNA,
The European Breast
Cancer Coalition
founded
l Xeloda is the
first oral 5-FU
chemotherapy
approved by the
FDA as monotherapy
for the treatment
of advanced breast
cancer
l Xeloda is
approved in
the US and
Europe for
the treatment
of advanced
colorectal
cancer
l Researchers
announce a new
screening test for
colon cancer that
detects specific
genetic abnormalities
in stool samples
of up to 70% of
patients with colon
cancer
l Researchers find
that a simple blood
test helps predict
colon cancer
l Europacolon, the
first Pan-European
Advocacy group
dedicated to
colorectal cancer is
founded
l Xeloda is approved
in the US and EU as
monotherapy for the
post-surgery treatment
of Dukes’ C (Stage III)
Colon Cancer
Xeloda is approved in l
Japan for the post-
surgery treatment of
Dukes’ C (Stage III)
Colon Cancer
Xeloda is approved in l
Europe in combination
with platinum-based
chemotherapy for
first-line use in
patients with advanced
stomach cancer
In Europe, Xeloda and Avastin l
are approved in combination
with any chemotherapy in
all lines of treatment for
advanced colorectal cancer.
Patients can now benefit from
these innovative treatments
Study showing l
Xeloda’s potential
as a pre-operative
(neo-adjuvant)
treatment for early
breast cancer
Two pharmacologists l
Louise Goodman
and Alfred Gilman
use nitrogen mustard
to treat a patient
with Non-Hodgkin’s
lymphoma and
demonstrate for
the first time that
chemotherapy can
induce tumour
regression
Xeloda Era
ChemotherapyThrough theYears: Celebrating 10Years of Xeloda
20022001 20041998199319721963 19651942 1953460
BC
2005 2007 2008
l Xeloda is
approved
in the US in
combination with
docetaxel for
the treatment of
advanced breast
cancer
l Xeloda is approved
in Europe in
combination with
docetaxel for
the treatment of
advanced breast
cancer
2003
l Researchers in Cambridge
show that the lifetime risk
of developing breast cancer
is doubled in most women
who carry a faulty CHEK2
(checkpoint kinase, 2) gene
Mark Skolnik and co-workers l
discover the BRCA1 (breast
cancer,1) gene, while Mike
Stratton and co-workers
discover the BRCA2 gene.
British epidemiologists
predict that a woman with
a mutation in BRCA1 has
approximately 85 percent
chance of developing breast
cancer if she lives beyond
the age of 70
1994
/5
l William Halstead
develops the radical
mastectomy believing
that cancer can be
cured by surgically
removing the tumour
and surrounding tissues
1829
Pre-Xeloda
1882
Roche develops l
5-fluorouracil
(5-FU), a
chemotherapy drug
used to treat many
cancers
l Xeloda reaches
blockbuster status and
has now treated in
excess of 1.5 million
patients
l Anticipated
completion of study
showing efficacy
of Xeloda with or
without Avastin in
early stage colon
cancer
1958
Xeloda: Advances in Gastrointestinal CancerTreatment
Xeloda: Advances in Breast CancerTreatment
l Xeloda approved in Japan
for the treatment of
patients with inoperable
or recurrent breast
cancer
More to Come
l Data showing
Xeloda efficacy as
a post-operative
(adjuvant)
treatment of
breast cancer
expected

4. 5
Portfolio | Jim Winslow
> Posters
Vaccines have saved millions of lives, mainly babies
and children.
True. Before vaccines were available to protect us, millions of children and adults in the United States lost their lives or
were permanently harmed due to deadly infections like polio, whooping cough (pertussis) and flu (influenza). But now, many
of these diseases have virtually disappeared, thanks to vaccines! However, if parents don’t continue to vaccinate children,
many of these diseases can, and will, return.
Vaccines prevent more than a dozen potentially deadly
diseases in children by age 2.
True. By the time children reach age 2, today’s vaccines can protect against serious diseases including chickenpox (varicella),
whooping cough, diphtheria, tetanus, polio, measles, mumps, rubella, Hib disease, hepatitis A & B, rotavirus, pneumococcal
disease (pneumonia, blood infections and meningitis) and flu. That’s 14 diseases your child is protected against with vaccines!
Because of vaccines, some diseases no longer occur in the
United States.
True. Since vaccines for polio and smallpox came into everyday use, neither disease occurs in the United States. In fact,
vaccination efforts have been so effective that smallpox doesn’t occur anywhere in the world!
Vaccination is one of the top public health achievements
over the last 100 years.
True. Vaccination is considered to be one of the “Ten Great Public Health Achievements in the 20th Century.”* In fact,
vaccination is at the top of the list! Why? Because vaccines protect children against many diseases that were feared
generations ago. (*According to the Centers for Disease Control and Prevention)
You should talk to your health care provider about how
on-time vaccination can help protect your baby.
True. Your health care provider has played a big role in helping to protect children through vaccination and can answer any
questions you have. By working with your provider, you can help ensure that your child is healthy and fully protected!
TWO FOR 2
Adherence Campaign
rue Or alse?
T F
What’s also true is that vaccination is one of the easiest ways to
guarantee that your child remains healthy and is protected between
birth and 2 years of age—when they need it the most!
Este anuncio es posible gracias al apoyo de Sanofi Pasteur Inc.
Programa de Vacunas para Niños
(Vaccines for Children)
Pregunte a su proveedor de atención médica o al departamento de salud
local cómo acceder a vacunas gratis o a bajo costo para niños y adolescentes.
n Los niños y los adolescentes corren el riesgo
de contraer enfermedades potencialmente
mortales como la gripe, la meningitis, la tos
convulsa y el virus del papiloma humano
(human papillomavirus, HPV).
n Sólo alrededor de la mitad de los adolescentes
hispanos en los EE. UU. reciben la vacunación
contra estas graves enfermedades infecciosas.
¡Ayude a proteger
la salud de sus hijos
vacunándolos!
Vacunas gratis o a bajo
costo para niños y
adolescentes
Busque su departamento
de salud local mediante
el código postal en
www.naccho.org/widget
CHAUNCEY BILLUPS SAYS…
“KEEP TEENS IN THE GAME!”
Defend Teen Health
Get Teens Vaccinated
(c)2010NBAEntertainment.PhotobyNoahGraham(NBAE/GettyImages).Allrightsreserved.
Visit VACCINESFORTEENS.NET for more information
Teens may be at risk for serious
and potentially life-threatening
diseases like meningococcal
meningitis, whooping cough,
and the flu.
Vaccination is a safe
and effective way to
help protect them.
Just like on the
basketball court,
the best offense
is a good defense.
Almost Everything You
Ever Wanted to Know About
A Short Course on How Vaccines Work
Almost Everything You
Ever Wanted to Know About
A Short Course on How Vaccines Work
Almost Everything You
Ever Wanted to Know About
A Short Course on How Vaccines Work
Sponsored by Fondation Mérieux and the AIDS Vaccine Advocacy Coalition
Support provided by sanofi pasteur
Sunday, 13 August 10:15-12:15
Level 200
Skills Building Room 8
n Where is the AIDS vaccine?
n Cellular responses, antibody responses…what do
they really mean?
n What’s being studied today, and what’s in the pipeline
for tomorrow?
The program is open to all conference attendees
Breakfast will be served

5. 6
Portfolio | Jim Winslow
> Postcards
Thisprogramhasbeenapprovedfor
2.4NAPNAPcontacthoursofwhich
1.2arepharmacologycontent.
AccreditationStatement:SanofipasteurhasbeengivenmeetingspacetoprovideaneducationalofferingduringNAPNAP’sAnnualConference.
NAPNAP’sapprovalofmeetingspaceorcontinuingeducationcreditdoesnotimplyproductendorsement.
CHILDREN
WITH ASTHMA
AND INFLUENZA
Practice Models for Improving Influenza
Immunization Rates Among Children with Asthma
You are invited to
attend a NAPNAP
contact hour
satellite symposium
Friday, March 31, 2006
Dinner and Registration: 6:30 p.m.
Presentations: 7:00 p.m.
Marriott Wardman Park Hotel, Salon 1
Washington, D.C.
Made possible by support from sanofi pasteur
To learn more, visit: www.abbottglobalcare.org
Using Innovative Programs and
Groundbreaking Technologies
to Improve Health
An AMPATH counselor, using a PDA and
a GPS device, provides home-based HIV
counseling and testing,TB screening,
Malaria bed nets and de-worming
medication as part of an Abbott Fund pilot
project in Turbo,Western Kenya.
Picturing
Hope
Through Their Eyes
Photo: Revathi, Age 14
The Asia Society Invites You to a Special Event and
Exhibition in Commemoration of World AIDS Day
Picturing Hope
Through Their Eyes
This display of photographs, taken by children in India, provides a close look at how the global
HIV/AIDS epidemic is shaping everyday lives. The images are selected from Picturing Hope,
a program dedicated to providing children impacted by HIV/AIDS with resources to explore their
feelings, strengthen their sense of self, and find a voice with which to tell their stories.
Tuesday, November 29, 2005
Opening Reception 6:30–8:30 p.m.
Remarks and program at 7:00 p.m.
Complimentary Admission, RSVP Requested. Limited Space Available.
Asia Society and Museum, 725 Park Avenue at 70th
street, New York City
To accept this invitation, please call the Asia Society Box office at 212-517-ASIA,
or email: boxo@asiasoc.org
Made possible by an unrestricted grant from the Abbott Fund
Watch Videos Featuring Tips From:
Shelley K., Epilepsy Advocate, mother and caregiver of a college-bound
21-year-old daughter diagnosed with epilepsy at age six. and who is
Heather E., Epilepsy Advocate, diagnosed with epilepsy while in college,
married for 13 years, raising two young children, and working toward an
advanced degree in the legal field.
Blanca Vazquez, MD, provides perspective on how epilepsy uniquely
affects women. Dr. Vazquez is an epilepsy specialist and assistant professor at the NYU School of Medicine.
Women Succeeding with Epilepsy
To watch, go to EpilepsyAdvocate.com or HealthyWomen.org
Succeeding
with Epilepsy
Beth Battaglino, RN, Executive
Director, HealthyWomen
Blanca Vazquez, MD, NYU School
of Medicine
Heather E., Epilepsy Advocate Shelley K., Epilepsy Advocate
Hear personal stories from real women who have faced and
overcome the unique challenges posed by epilepsy
This symposium is made possible by an unrestricted educational grant to the National Meningitis Association from GlaxoSmithKline.
The Role Nurse Practitioners Play in
Preventing Meningococcal Disease
To the National Meningitis Association’s Non-CE Educational Symposium:
Speakers will include:
Mary Beth Koslap-Petraco, DNP, CPNP, Coordinator Child Health, Suffolk County
Department of Health Services
Paul J. Lee, MD, Pediatric Infectious Diseases and International Adoption Program,
Winthrop-University Hospital
Lynn Bozof, President, National Meningitis Association
At NAPNAP’s 31st Annual Conference on Pediatric Health Care
Date: April 17, 2010 | Time: 7:00AM – 8:30AM
Location: Grand Ballroom AB
Breakfast will be served
To register, please visit http://www.nmaus.org/panel/events/ or call, 212-886-2214.
You’re Invited!
Availability is limited to the first 250 registrants.
Thursday, March 22, 2007
6:00–9:30 p.m.
At the NAPNAP 28th
Annual Conterence
Dinner and Registration: 6:00 p.m.
Presentations: 7:00 p.m.
Disney’s Coronado Springs Resort, Fiesta 6
Lake BuenaVista, FL
TWO FOR 2
Adherence Campaign
Made possible by support from sanofi pasteur
Strategies to Facilitate Parent-Provider Dialogue
to Encourage On-Time Vaccination by Age 2
REGISTER NOW!
Pre-registration now available
On-site registration available
E-mail: twofor2@cooneywaters.com
Phone: (212) 886-2250
This program is pending approval by the National Association of Pediatric Nurse
Practitioners (NAPNAP) for 1.2 NAPNAP contact hours.

6. 7
Portfolio | Jim Winslow
> Brochures/Programs
XV International AIDS Conference
Bangkok, Thailand; July 11-16, 2004
CD-ROM Abstracts
Ten Years of Mobilizing and Strengthening Community
Responses to HIV/AIDS in Burkina Faso
The experience of IPC and the International HIV/AIDS Alliance, results and les-
sons learned
Lead Author: B. Millogo – IHAA
Scaling up Community Mobilization and Responses to HIV/AIDS
Through Secondary Mobilization of CBOs
The experience of IPC/BF in Burkina Faso
Lead Author: D. Bassonon – IHAA
Role and Place of Social Welfare Organizations in the Emer-
gence of Community Responses to HIV/AIDS in Burkina Faso
The case of Association Solidarité et Entraide Mutuelle au Sahel (SEMUS);
Solidarity and Mutual Help in the Sahel
Lead Author: M. Yameogo – IHAA
Institutions, Communities and the Continuum of Care for
Children Affected by AIDS
Lead Author: J. Parker – Development Alternatives Inc.
Building an AIDS-in-the-Workplace Program in Developing
Country Offices
Lessons learned from Abbott Laboratories
Lead Author: J. Richardson – Abbott Laboratories Fund
Powerful Techniques to Reduce Stigma and Discrimination
Against Children and PLHA
Lead Author: S. Ghosh – IHAA
Community Support to PLWA
The experience of Etre Comme Les Autres (ECLA) in Burkina Faso
Lead Author: M. Bologo – IHAA
Through its Global Care Initiatives – Step Forward, Tanzania Care, Determine®
HIV Testing Donation Program and Abbott Access – Abbott Laboratories and the
Abbott Laboratories Fund work closely with governments, nongovernmental
organizations (NGOs) and industry partners to create programs to fight AIDS in
the developing world. In collaboration with Axios Foundation, Baylor College of
Medicine, the International HIV/AIDS Alliance, and the governments of Tanzania
and Burkina Faso, Abbott is pleased to present this overview of oral sessions,
poster presentations, CD-ROM abstracts and satellite sessions at the
XV International AIDS Conference.
www.abbottglobalcare.org
Contact Info
Reeta Roy, Divisional Vice President
Global Citizenship and Policy
100 Abbott Park Road, Bldg. AP6D-2, Dept. 383
Abbott Park, IL 60064
Office: 847.936.0645 • Fax: 847.937.9555
reeta.roy@abbott.com
www.abbottglobalcare.org
Jeff Richardson, Executive Director
Step Forward and Tanzania Care Programs
1801 K Street, NW 10th Floor
Washington, D.C. 20006
Office: 202.530.4741 • Fax: 202.530.4744
jeff.richardson@abbottfund.org
www.stepforwardforchildren.org
www.tanzaniacare.org
Rob Dintruff, Executive Director
Access to HIV Care and PMTCT Donations Programs
200 Abbott Park Road, Bldg. AP34-3, Dept. O6MQ
Abbott Park, Illinois 60064
Office: 847.938.7945 • Fax: 847.938.8497
rob.dintruff@abbott.com
www.accesstohivcare.org
www.pmtctdonations.org
Satellite Sessions
The Need to Know
Accelerating Access to Testing
Global Business Council
Location: Royal Orchid Sheraton
Saturday, July 10, 2004 2-6PM
From Hope to Reality
A summit on the U.S. President’s Emergency Plan for AIDS Relief
Global Health Council
Location: Room B Exhibition Hall
Sunday, July 11, 2004 1:30-6:30PM
Combating Stigma and Discrimination
The Role of Religious Leaders in Building Inclusive Communities
World Conference of Religions for Peace Ecumenical Advocacy Alliance, UNAID
Location: Conference Hall K
Monday, July 12, 2004 8:15-10:15PM
State-of-the-Art Management of ARVs
An Interactive Electronic Session
Axios
Location: Room C Exhibition Hall
Tuesday, July 13, 2004 6-8PM
From Policy to Implementation
Leveraging the Power of Industry
Global Business Council
Location: Room G Exhibition Hall
Wednesday, July 14, 2004 12-2PM
Overview of Sessions
and Presentations for
Abbott Global Care
Initiatives and Key
Partners
In Collaboration With
XV International AIDS Conference
Bangkok, Thailand; July 11-16, 2004
������
����������
��������Texas Medical Center, Houston, Texas
A Photo Exhibit by Children
Picturing Hope is a project that helps orphans and
vulnerable children impacted by HIV/AIDS share their
hopes and dreams through photography. The photos
were taken by children from Burkina Faso, India, Mexico,
Romania and Tanzania and can be seen at Booth 21 in the
main Exhibit Hall. Step Forward underwrote this program.
For the 2 million Tanzanians
estimated to be living with
HIV/AIDS, access to basic health
services, counseling and
treatment is nearly unattainable
due to a shortage of specialized
staff, inadequate infrastructure and
facilities, and scarce resources.
Consequently, HIV/AIDS continues
to hinder Tanzanian communities
to an alarming degree.
For more information contact:
Jeff Richardson, Executive Director
Tanzania Care
1801 K St., N.W.
10th Floor
Washington, DC 20006
Office: 202.530.4741 • Fax: 202.530.4744
Cell: 202.258.1755
jeff.richardson@abbottfund.org
©2004, Abbott Laboratories, printed in USA
Printed on Recycled Paper
Tanzania Care is a partnership among Abbott
Laboratories, the Abbott Laboratories Fund
and the government of Tanzania to modernize the
country’s public health care facilities and
systems, and improve services and access to
care for people living with HIV/AIDS and other
serious illnesses.
28
28th Annual Dinner & Awards Presentation
th Annual Dinner &
Awards Presentation
Dr. Walter A. Orenstein
Sponsored in part by an unrestricted grant from sanofi pasteur
D
r. Orenstein is director of Emory University’s Program for Vaccine
Policy and Development and associate director of the Emory Vaccine
Center. He received his bachelor’s degree at The City College of New
York and his medical degree from the Albert Einstein College of Medicine.
He completed an internship and a residency in pediatrics at the University of
California, San Francisco, followed by a fellowship in infectious diseases at the
University of Southern California Medical School and a residency in preventive
medicine at the U.S. Centers for Disease Control and Prevention (CDC).
Dr.Orensteinhasdevotedhiscareertoworldwideimmunizationagainstinfectious
diseases. Prior to joining Emory in March 2004, he had a 26-year career at the
CDC. He was director of the agency’s National Immunization Program, where
he led successful efforts combating the occurrence of once-common childhood
diseases, protecting adults from vaccine-preventable diseases, expanding vaccine
safety efforts and promoting the use of immunization registries.
Major policies adopted during his tenure include recommendations for a second
dose of measles, mumps, rubella vaccine for all children; universal vaccination
of children against Haemophilus influenzae type b, hepatitis B, varicella and
invasive pneumococcal disease; and annual influenza vaccination of all 50-64
year-old adults and 6-23 month-old children. He served as the agency’s liaison
member to the National Vaccine Advisory Committee and the American
Academy of Pediatrics Committee on Infectious Diseases.
Dr. Orenstein has served as an Assistant Surgeon General of the U. S. Public
Health Service and currently is chairman of the World Health Organization’s
Technical Consultative Group on the Global Eradication of Poliomyelitis. In
addition, he has been a consultant to the Pan American Health Organization.
Dr. Orenstein is a member of the International Editorial Board for the journal
Vaccine. Along with Dr. Stanley Plotkin, he co-edits “Vaccines, 4th edition,”
the definitive textbook in the field. He is a fellow of the American Academy
of Pediatrics, Infectious Diseases Society of America and Pediatric Infectious
Diseases Society. He has served on the Council of the Pediatric Infectious
Diseases Society, chaired its Publications Committee and is the outgoing
Secretary-Treasurer.
Monday, May 1, 2006
The Palace hoTel
San FranciSco, ca
Protect. Learn. Understand. Safeguard.
Educatingolderadultsaboutinfluenzaandprevention
FromtheNationalCouncilonAgingandSanofiPasteur
To Learn More
Flu + You is a program of the National Council
on Aging in collaboration with Sanofi Pasteur
to educate older adults about the seriousness
of influenza, the importance of vaccination, and
available vaccine options for older adults.
Talk to your health care provider today about
your risk for influenza and the vaccination
options that might be right for you.
Visit www.ncoa.org/Flu.
Vaccination Options
for Adults 65 and Older
As we age, the body’s ability to fight disease
declines due to a weakening of the immune
system, which results in the body producing
fewer antibodies to help fight infection from
the flu virus.
Recent studies have shown that the traditional flu
vaccine might not work as well for people 65 years
of age and older as it does for younger people.
The age-related decline in the immune system
affects the body’s response to vaccination.
Adults 65 and older have two vaccine options
available—the traditional flu shot and a higher
dose flu vaccine. The higher dose vaccine is
designed specifically for this population to
address the age-related decline of the immune
system by triggering the body to produce more
antibodies against the flu virus than would be
produced by the traditional flu shot.
Both vaccine options are covered by Medicare
Part B with no copay.
To learn more, visit www.ncoa.org/Flu.
Protect. Learn. Understand. Safeguard.
Educatingolderadultsaboutinfluenzaandprevention
FromtheNationalCouncilonAgingandSanofiPasteur
COM 10642
Join us for 15 minutes of fame...
Bio 2006
... and a few hours of
conversation and fun
Continuing Education (CE)
Children with Asthma and Influenza:
Practice Models for Improving Influenza
Immunization Rates Among Children with Asthma
Program Overview
Asthma is the most common chronic
medical condition among children,
affecting more than six million chil-
dren younger than 18 years of age in
the U.S.
Despite longstanding recommenda-
tions by the CDC, influenza vaccina-
tion rates among children with asthma
remain seriously low. Children with
chronic medical conditions, includ-
ing asthma, are at an increased risk for
influenza-related complications (e.g.,
pneumonia, increased outpatient vis-
its and antibiotic prescriptions).
Highlights will be scientific data dem-
onstrating the impact of influenza in
children with asthma. This program
will also focus on practical methods
PNPs can employ to increase influ-
enza immunization rates among the
pediatric population they serve.
Providers agree on the severity of in-
fluenza among children with asthma.
However, most practices do not have
an infrastructure in place to help
identify, recall and annually immu-
nize these children.
This CE program will feature several
strategies and models implemented in
a variety of practice settings that have
been successful in maximizing pedi-
atric asthma influenza immunization
rates. It is designed to help PNPs, NPs
and nurses have a significant positive
impact on influenza vaccination rates
among their pediatric patients, partic-
ularly for those with chronic medical
conditions such as asthma.
Cooney/WatersGroup
141FifthAve,9thFloor
NewYork,NY10010
Aninvitationtoa
NAPNAPcontacthour
satellitesymposium
RegisterNow!e-mail:rsvp@asthmaflu.com
212-886-2265
AccreditationStatement:SanofipasteurhasbeengivenmeetingspacetoprovideaneducationalofferingduringNAPNAP’sAnnualConference.
NAPNAP’sapprovalofmeetingspaceorcontinuingeducationcreditdoesnotimplyproductendorsement.
CHILDREN
WITH ASTHMA
AND INFLUENZA
Practice Models for Improving Influenza
Immunization Rates Among Children with Asthma
This program has been approved for 2.4 NAPNAP
contact hours of which 1.2 are pharmacology content.
You are invited to attend
a NAPNAP contact hour
satellite symposium

7. 8
Portfolio | Jim Winslow
> Monographs/Reports
Making Adult
Vaccinations Routine
to Reduce Preventable Death and Disability
A Call to Action
from the National
Foundation for
Infectious Diseases
and the Infectious
Diseases Society of
America
Strategies for Success
Case Studies in Enhancing
Adult and Adolescent Immunization
Immunization
Best Practices
for Public Health ProfessionalsImmunization Best Practices
for Public Health Professionals
MKT14287 Best Practices.indd 1 7/8/08 10:21:16 AM
Supported by an unrestricted educational grant to the National Foundation for Infectious Diseases from sanofi pasteur
Identifying and Overcoming
Barriers to Improved Influenza
Immunization Rates in this
High-risk Population
Influenza
and Children
with Asthma
Call to
Action
> Sample of Covers
Keys to Successful Management
of Allergy Patients:
Focus on Consumer Confidence, Compliance and Satisfaction
A closed-door roundtable convened by the
American Academy of Otolaryngic Allergy
January 6, 2006, Westin O’Hare
Rosemont, Illinois
COMPLIANCE
ALLERGIES

8. 9
Portfolio | Jim Winslow
> Monographs/Reports Layout
National Data Show
Immunization Gaps for All Vaccines
In 2008, the CDC reported second-year results from
the National Immunization Survey-Teen (NIS-Teen). This
national survey assesses adolescent vaccination rates
based on data gathered from health care providers.4
None of the vaccines in the survey had coverage rates
of 90 percent, the goal established by “Healthy People
2010,” the Department of Health and Human Services’
national preventive health care initiative (Figure 1).5
Rates were higher for the catch-up vaccines, likely
because they have been on the immunization schedule
for a longer time, and lower for the newer vaccines.
U.S. Adolescents Are
Vulnerable to Vaccine-
Preventable Diseases
Vaccines recommended for adolescents are underused,
leaving our nation’s teens vulnerable to serious morbid-
ity and even death. Health care providers should make
every effort to vaccinate adolescents according to our
national immunization schedule to benefit adolescents,
their close contacts and society at large.* The U.S.
immunization schedule is the product of careful and
extensive review of all aspects of vaccines (e.g., effec-
tiveness, safety, cost) by a 15-member expert panel, the
Advisory Committee on Immunization Practices (ACIP),
and the adoption of the committee’s recommenda-
tions by the Centers for Disease Control and Prevention
(CDC) in collaboration with the American Academy of
Pediatrics, the American Academy of Family Physicians
and other professional organizations.1
Vaccines recommended for use in adolescents can be
grouped into several categories (Table 1).2
Influenza vac-
cine is recommended every year for all children, including
adolescents, up to age 18. Three more recently licensed
vaccines are recommended for first-time administration
during adolescence. “Catch-up” vaccines, which have
been available for a longer time, are for administration to
adolescents who were not immunized or were under-
immunized as infants and toddlers. There are also three
vaccines recommended for use in certain high-risk ado-
lescent subpopulations.Together, these vaccines protect
adolescents from 14 infectious diseases.
Achieving and maintaining high immunization rates is
critical for disease prevention. The highly effective U.S.
childhood immunization program has led to elimination
of smallpox, greater than 99 percent reductions in diph-
theria, measles, polio and rubella, and to a greater than
90 percent reduction in mumps, tetanus and pertussis.3
These successes are rooted in widespread infant and
toddler vaccination. Widespread immunization of ado-
lescents can lead to similar positive results.
However, it is encouraging to note that rates for all vac-
cines increased compared with data from the first NIS-
teen report in 2007. Of the vaccines on the schedule for
at least five years, MMR vaccine coverage is highest at
89 percent and tetanus-containing vaccine coverage
is lowest at 72 percent. The latter is a combined rate
that includes vaccination with either the older tetanus
and diphtheria vaccine (42 percent) or with the newer
Tdap vaccine (30 percent), which includes acellular
pertussis. Inclusion of pertussis is particularly impor-
tant because pertussis has been on the rise in the U.S.
since 1976.6
Vaccines Prevent Serious
Morbidity and Mortality
Vaccine-preventable diseases can cause serious
morbidity and mortality in adolescents and their close
contacts. Even when treated quickly and appropriately,
meningococcal disease kills about 10 to 14 percent
of people infected, and 11 to 19 percent of survivors
suffer serious long-term effects such as hearing loss,
brain damage and digit or limb amputation.7-9
About
70 percent of cases of meningococcal disease in U.S.
adolescents are caused by strains included in the vac-
cine.10
Vaccinating adolescents at 11-12 years of age is
important because adolescents are at increased risk of
meningococcal disease.11
Pertussis is substantially underreported, making it
difficult to pinpoint U.S. incidence,12
but some estimates
range from 1 million to over 3 million cases per year.13,14
Whether cases in adolescents are subclinical, of minor
clinical importance or more severe, infected adoles-
cents may serve as an important reservoir of infection
for neonates and others at higher risk of serious illness
or pertussis-related death.15-18
Tdap is a highly effective
vaccine that replaces the previously recommended Td
vaccine as the booster at 11-12 years of age or in older
adolescents who need a Td booster.2
There are over 6 million new human papillomavirus
(HPV) infections in the U.S. each year; nearly three in
four are in females 15-24 years of age.19
While most of
these infections will be cleared by the immune system,
infection can lead to cervical cancer. The three-dose
HPV vaccine series provides protection against genital
warts and two HPV types (16 and 18) that cause about
70 percent of cervical cancers.20
Catch-up vaccines are more widely used,
leading to substantial disease prevention
The catch-up vaccines are associated with much higher
vaccination rates and, therefore, with much greater ben-
efits to date. For example, from 1990 to 2004, incidence
of acute hepatitis B declined 75 percent as infant
immunization increased;21
the last indigenous case of
polio reported in the U.S. was in 1979;22
and, since the
introduction of vaccines to combat measles, mumps
and rubella, U.S. incidence of these illnesses has
decreased 99 percent.23
Adolescent Vaccination
2 3 4
Bridging from a strong childhood foundation to a healthy adulthood
Influenza vaccine recommendations
expanded to include all adolescents
In 2008, CDC expanded its influenza recommendations
to include annual immunization of all children 6 months
to 18 years of age.24
Influenza kills more
Americans every year
than all other vaccine-
preventable diseases
combined.25
While
deaths in children are
not common, they do
occur in children of all
ages and health status.
In the 2003-2004
season, 37 percent
of the 153 pediatric
deaths reported were
in children 5 to 18 years of age and 67 percent were in
children with no underlying risk factor26
A Broad Approach Is Necessary
to Increase Vaccination Rates
Barriers to increased immunization* rates can be
grouped into three main categories: family- or patient-
related, provider-related and system-related. All three
need to be addressed if immunization rates in adoles-
cents are to be increased.
One of the most important issues facing adolescents
is less than optimal use of medical homes and lack of
regular well-care visits. Most primary care visits for ado-
lescents are not preventive visits.27
Therefore, a compre-
hensive health care visit is recommended for all adoles-
cents at 11-12 years of age.28
Making this visit routine for
all adolescents would provide an opportunity to deliver
much needed preventive health services, including
vaccines. However, the absence of such a routine visit
should not deter health care providers from using all
other opportunities (e.g., visits for illness or injury, sports
physicals) to provide vaccines or education and counsel
about the importance of immunization. The end-of-high-
school/college entry point is also a great time to review
immunization status and provide necessary vaccines
before insurance coverage changes.
Changing behavior among adolescents and their parents
or guardians will require education and outreach. While
younger children have little or no control over health care
decisions, adolescents often play a key role in decision
making. Therefore, it is important that adolescents, as
well as their parents or guardians, are educated about
the value of vaccines and the seriousness of vaccine-
preventable diseases. Once empowered, adolescents
and their parents or guardians may generate discussion
with their health care providers about vaccines and other
preventive health measures.
Health care providers must prepare if they are to meet
increased demand for immunization against vaccine-
preventable diseases in adolescents. They can establish
standing orders for vaccination services, use existing
immunization information systems, develop vaccina-
tion “quick visits,” especially for multiple dose vaccines,
establish office guidelines for vaccine delivery, imple-
ment reminder and recall systems, create immuniza-
tion teams (or an immunization leader in the practice)
whose job is to focus on this issue, and use the CDC’s
Comprehensive Clinic Assessment Software Applica-
tion (CoCASA†
) to assess office immunization practices.
Health care providers also need to educate themselves
and their colleagues about vaccines and the diseases
they prevent.
However, even if every traditional vaccinator in the coun-
try were perfectly prepared, delivery of all recommended
vaccine doses to adolescents would remain a challenge.
Vaccinations administered at alternative sites, like schools
and pharmacies, may be an integral component of opti-
mal immunization efforts.
System-related vaccination barriers are not remedied
easily by the action of individual health care providers or
the public. However, supportive efforts to minimize such
barriers (e.g., a nationwide immunization tracking system
and a vaccine financing system that allows adolescents
to receive all necessary vaccines, without cost barriers, at
their medical home location) may be instituted.
Source: CDC. MMWR. 2008;57(40):1100-1103.4
*Coverage among teens without a reported history of disease.
†
HPV rates among adolescent females only.
Hep=hepatitis; Men=meningococcal disease; NA=not available;
Tet=tetanus–containing vaccine; Var=varicella.
Hep B
(≥3)
MMR
(≥2)
Tet
(≥1)
HPV†
Var*
(≥1)
Men
(1)
Percent Immunized
0
20
40
60
80
100
89 88
76
72
32
25
30
Tdap
42
Td
Vaccine (No. of Doses)
Figure 1
Vaccination Rates in Adolescents
13-17 Years of Age, U.S.—2007
†
Information about CoCASA is available at http://www.cdc.gov/vaccines/pro-
grams/cocasa/default.htm.
*NFID refers readers interested in this topic to the following publication, released
as this Call to Action was being completed: Strengthening the Delivery of New
Vaccines for Adolescents. Pediatrics; 2008 Jan;121(Supplement 1).
*A CME-accredited monograph, Roadmaps for Clinical Practice: Improving
Adolescent Immunizations–A Primer for Physicians, is available from the American
Medical Association at http://www.ama-assn.org/ama/pub/category/6886.html.
Table 1
Vaccines for Adolescents*
Vaccines for routine administration to all
Adolescents†
n Influenza (1 dose annually)
n Human papillomavirus (3-dose primary series)
n Meningococcal conjugate vaccine (1 primary dose)
n Tetanus, diphtheria and acellular pertussis (1
booster dose)
Catch-up vaccines for adolescents not fully
immunized previously
n Hepatitis B
n Inactivated polio
n Measles, mumps and rubella
n Varicella‡
Vaccines for certain high-risk adolescents
n Hepatitis A
n Pneumococcal polysaccharide
*See MMWR for each vaccine for detailed information.
†
Influenza vaccination needed annually, all other recommended at 11-12
years of age.
‡
As of 2006, two doses are recommended (at 12-15 months and 4-6 years).
Adolescents who received one dose should have a catch-up dose.
Source: CDC. MMWR. 2008;57(01):Q1-Q4.2
This publication made possible by an unrestricted educational grant to the
National Foundation for Infectious Diseases by sanofi pasteur.
Editorial Board
William Schaffner, MD, Chairman
Dennis A. Brooks, MD, MPH, MBA
Hal B. Jenson, MD
Linda Juszczak, DNSc, MPH, CPNP
Bonnie M. Word, MD
Adolescent Vaccination
Bridging from a Strong Childhood
Foundation to a Healthy Adulthood
A report on strategies to increase
adolescent immunization rates

9. 10
Educating About Adolescent Meningitis Prevention
A National Meningitis Association Program
Parent TeacherAwareness
the
ShotsA Meningococcal Disease Awareness Program
Targeting Adolescents and Young Adults
Calling
A VNAA program supported by sanofi pasteur
Portfolio | Jim Winslow
> Logos
S
w
Succeeding
with Epilepsy
Succeeding
with Epilepsy
Unpublished Logo Comp for
Lupus Awareness Campaign
Listen to Epilepsy
AdvocateTM
Listen to Epilepsy
AdvocateTM
Listen to Epilepsy
AdvocateTM
EpilepsyAdocate.com
Visit
EpilepsyAdocate.com
Visit
EpilepsyAdocate.com EpilepsyAdocate.com
become our fan
on facebook
become our fan
on facebook
become our fan
on
facebook
EpilepsyAdocate.com
Visit
Logo for National NCOA Awareness Initiative
Vaccinol
A Short Course on How Vaccines Work
And How They Might Work for You
A Short Course on How Vaccines Work
And How They Might Work for You
Almost Everything You Ever
Wanted to Know About
Almost Everything You Ever
Wanted to Know About
Vaccinology A Short Course on How Vaccines
And How They Might Work for Yo
Almost Everything Yo
Wanted to Know Ab
Vaccinol
A Short Course on How Vaccines Work
And How They Might Work for You
Almost Everything You Ever
Wanted to Know About
Vaccinology
A Short Course on How Vaccines Work
And How They Might Work for You
Almost Everything You Ever
Wanted to Know About
Vaccinology
A Short Course on How Vaccines
And How They Might Work for Yo
Almost Everything Yo
Wanted to Know Ab
A Short Course on How Vaccines
And How They Might Work for Yo
Almost Everything Yo
Wanted to Know Ab
Vaccinol

10. 11
Portfolio | Jim Winslow
> Collateral Materials for Abbott Fund
Health at Home/Kenya—A GBC Impact Initiative to Fight AIDS, TB and Malaria
GBC
GLOBAL BUSINESS COALITION
ON HIV/AIDS,TUBERCULOSIS AND MALARIA
AFFORDABLE QUALITY HEALTH CARE
GBC
GLOBAL BUSINESS COALITION
ON HIV/AIDS,TUBERCULOSIS AND MALARIA
Health at Home | Kenya
Home-based Counseling and Testing – HCT
for 2 Million People in Western Kenya
A GBC Impact Initiative
United Republic of Tanzania
Ministry of Health
and Social Welfare
Abbott Fund is working with partners
on the ground to improve the health
of communities around the world.
To learn more, visit: www.abbottfund.org
Healthy People, Stronger Communities
This young Cambodian girl and her mother receive health care education and
other services from Abbott Fund-supported Angkor Hospital for Children.
An initiative of CUH2A
Mt. Meru Hospital regional laboratory modernized by Abbott Fund in 2007
State of many health laboratories in Tanzania
MOHSW
n Leadership, coordination and
oversight of project
n Commitment to scaling-up
HIV/AIDS response in
Tanzania
n Nationwide laboratory needs
assessment
n Existing partnerships with
CDC and Abbott Fund
Abbott Fund Tanzania
n Funding for National
Laboratory Modernization
Project
n Experience in project
management
n Experience in laboratory
improvements in Tanzania
n Commitment to support
MOHSW in Tanzania
D4O
n Expertise in laboratory
design
n Experience in
project planning and
implementation
CDC-Tanzania
n Scientific expertise
n Coordination of partners’
contributions and liaison
between partners,Tanzania
PEPFAR team and USG
headquarters offices
APHL
n Collaborative partnership
n Expertise in public health
laboratory management and
operations
n Experience in Tanzania
laboratory system
Implementing Partners
Public-Private Partnership
We would like to invite you
to join us for a reception to celebrate
the opening of our new Abbott Fund
office in Dar es Salaam and
the opportunity to meet with
Abbott Chairman and
CEO, Miles D. White
June 27, 2007 6:00-7:30 P.M.
Abbott Fund Offices | 17th Floor, PPF Towers
Corner of Garden and Ohio, Dar es Salaam
RSVP: ������� ������ �� ���������������������������: ��������� �������������� ������ �� ���������������������������: ��������� ��������� ���������������������������: ��������� ���������������� �������
To learn more, visit: www.abbott.com/haiti
Photo: Brett Williams/Direct Relief International
Abbott and the Abbott Fund are working directly with trusted partner organizations to assess and respond to
immediate health needs as well as longer-term recovery and rebuilding efforts in Haiti.
We salute our partners, other humanitarian aid organizations and the people of Haiti who are working tirelessly
to help rebuild the country.
Honoring Our Partners Who Are Helping Rebuild Haiti
To learn more, visit: www.abbottfund.org
Using Innovative Programs to
Combat NCDs and Improve Health
Abbott and the Abbott Fund are working with partners on the ground, in Kenya,
Bolivia and beyond to leverage innovative solutions to improve health outcomes.
Patient John’s story is representative of the struggle so many
patients face on a daily basis. John is employed as a driver,
transporting many life-saving supplies and Health Counselors
needed for providing HIV care, for the Academic Model Providing
Access to Healthcare (AMPATH). His recent diagnosis of diabetes
had threatened his very livelihood as the insidious complications
of diabetes were starting to set in and prevent him from
performing his job responsibilities. With just four months of care,
John became symptom free and is back to his regular duties as
one of AMPATH’s drivers. AMPATH is providing comprehensive
diabetes care services in rural areas of western Kenya where
none had previously existed and now cares for more than 2,000
diabetic patients. AMPATH integrates chronic disease care for the
approx. 300,000 patients who receive HIV/AIDS, prenatal, and
primary care services in its clinics.
Señora Montaño has had diabetes all her life, is blind in both
eyes and often needed hospitalization. She lives in Cochabamba,
Bolivia’s third-largest city, where more than 9 percent of the
population suffers from diabetes—Clinica Vivir con Diabetes
(CVCD), Abbott Fund and Direct Relief International’s local partner,
diagnoses and treats patients with diabetes throughout the city.
CVCD is the region’s only diabetes clinic, delivering care at little
or no cost to patients like Señora Montaño. CVCD sends trained
social workers to visit diabetes patients at home to ensure that
they know how to manage their condition. Señora Montaño got
a cane and plans to go to the clinic in the future. Over the past
five years, CVCD has served more than 66,000 diabetes patients,
counseling them on disease management techniques and
healthy living habits. CVCD’s annual rate of detection of diabetes
has also increased by 250 percent.